EarningsQ2 2026 Earnings Report
DE:XP0 Q2 2026 EPS Results
Actual EPS-€0.99
Consensus EPS-€1.02
Beat/MissBeat by +€0.03
One Year Ago EPS-€0.95
DE:XP0 Q2 2026 Revenue Results
Actual Revenue€0.00
Expected Revenue€1.48M
Beat/MissMissed by -€1.48M
YoY Revenue Growth―
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
DE:XP0 Upcoming Earnings
Xenon's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:XP0 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple substantive positive developments: an imminent NDA submission supported by strong Phase 3 efficacy and compelling long-term open-label data, a healthy cash position ($1.2B) providing runway into 2029, advancing early-stage pain programs (including confirmed central exposure for Nav1.7) and active commercial build-out with encouraging HCP feedback. Key risks highlighted include the inherent uncertainty of regulatory review, pending readouts for MDD and pain PoC studies, ongoing payer/pricing discussions, common TEAEs that may affect tolerability at higher doses, and potential competition from future Kv7 entrants. On balance, the company's strengths (efficacy, safety dataset, cash runway, advancing pipeline and commercial preparations) outweigh the outstanding uncertainties and execution risks.Company Guidance
NDA Submission on Track
Completed a productive in-person pre-NDA meeting with FDA and remain on track to submit the New Drug Application for Azetukalner (AZK) later this quarter; management emphasizes alignment with the agency on NDA components.
Strong Efficacy in Phase 3 X-TOLE2
X-TOLE2 met its primary endpoint and produced what management described as the best placebo-adjusted response in pivotal focal onset seizure (FOS) studies; dose-dependent reductions observed as early as week 1 and dose-dependent increases in ≥75%, ≥90% and 100% responder rates.
Robust Long-Term Open-Label Data
X-TOLE open-label extension (48-month) data show a 91% reduction in monthly seizure frequency for patients treated ≥48 months, ~40% of patients were seizure-free for ≥12 months and 25% were seizure-free for ≥2 years — notable long-term clinical durability signals.
Favorable Safety and Exposure Dataset
AZK demonstrated a generally well-tolerated safety profile consistent with prior studies; company reported >800 patient-years of safety/exposure data supporting tolerability across dose groups (common TEAEs: dizziness, somnolence, headache, fatigue).
Strong Balance Sheet and Runway
Cash, cash equivalents and marketable securities of $1.2 billion at quarter end, which management expects will fund operations into 2029 and support U.S. launch readiness and pipeline programs.
Broad and Advancing Pipeline
Advancing five additional Phase 3 studies of AZK across epilepsy and neuropsychiatry (including X-NOVA2, X-NOVA3 and X-CEED); X-NOVA2 top-line MDD data expected in H1 2027. Pain portfolio: XEN1701 and XEN1120 Phase 1 studies nearing completion with data supportive of moving to Phase 2 PoC in acute pain; new Nav1.7 candidate XEN1720 has initiated Phase 1 SAD/MAD.
Confirmed Central Exposure for Nav1.7 Program
XEN1701 Phase 1 confirmed cerebrospinal fluid exposure, supporting both peripheral and central target engagement consistent with preclinical efficacy modeling — strengthens rationale for advancing into Phase 2 proof-of-concept studies.
Commercial Build and Market Feedback
Commercial organization hiring underway (marketing, sales, payer-facing field team) with payers engaged; market research and HCP interactions show strong enthusiasm for AZK's novel mechanism, rapid onset, once-daily dosing and potential for earlier adoption by general neurologists.
DE:XP0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed